Surgical, radiation and medical oncologists in the Baylor St. Luke's Medical Center Dan L Duncan Comprehensive Cancer Center specialize in the diagnosis and treatment of head and neck squamous cell ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

New data presented at AACR supports adding pembrolizumab before and after surgery in patients with newly diagnosed locally ...

Head and neck ... cell carcinomas that originate from the epithelium of these regions. The clinical activity of neoadjuvant immunochemotherapy for treating locally advanced oral squamous cell ...

The addition of neoadjuvant and adjuvant pembrolizumab to standard of care significantly improved outcomes for certain ...

The drug's safety profile was consistent with that found in prior studies, with no new safety signals identified.

PDS Biotechnology has commenced the randomised, multi-centre Phase III clinical trial, VERSATILE-003, to assess the efficacy ...

today announced that a patient with HPV+ head and neck squamous cell carcinoma (HNSCC) has been dosed in the ongoing ACESOT-1051 clinical trial evaluating APR-1051. This is the first patient to be ...

Pembrolizumab (Keytruda) given before and after surgery to supplement adjuvant therapy improved responses and survival in ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...